155 related articles for article (PubMed ID: 18657973)
21. Disparities in BRCA testing: when insurance coverage is not a barrier.
Olaya W; Esquivel P; Wong JH; Morgan JW; Freeberg A; Roy-Chowdhury S; Lum SS
Am J Surg; 2009 Oct; 198(4):562-5. PubMed ID: 19800469
[TBL] [Abstract][Full Text] [Related]
22. Oral contraceptive use and BRCA penetrance: a case-only study.
Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
[TBL] [Abstract][Full Text] [Related]
23. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
[TBL] [Abstract][Full Text] [Related]
24. Cancer genetics.
Chapman DD
Semin Oncol Nurs; 2007 Feb; 23(1):2-9. PubMed ID: 17303511
[TBL] [Abstract][Full Text] [Related]
25. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity.
Ghadirian P; Narod S; Fafard E; Costa M; Robidoux A; Nkondjock A
Breast Cancer Res Treat; 2009 Sep; 117(2):417-22. PubMed ID: 19165595
[TBL] [Abstract][Full Text] [Related]
27. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
[TBL] [Abstract][Full Text] [Related]
29. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
[TBL] [Abstract][Full Text] [Related]
30. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis.
Karlan BY
Gynecol Oncol; 2004 Feb; 92(2):519-20. PubMed ID: 14766241
[No Abstract] [Full Text] [Related]
31. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
[TBL] [Abstract][Full Text] [Related]
32. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Powell SN; Kachnic LA
Oncogene; 2003 Sep; 22(37):5784-91. PubMed ID: 12947386
[TBL] [Abstract][Full Text] [Related]
33. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
34. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.
Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C
Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048
[TBL] [Abstract][Full Text] [Related]
35. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring.
Bradbury AR; Patrick-Miller L; Pawlowski K; Ibe CN; Cummings SA; Olopade OI; Daugherty CK
Am J Med Genet C Semin Med Genet; 2008 Feb; 148C(1):70-7. PubMed ID: 18200524
[TBL] [Abstract][Full Text] [Related]
36. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
37. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
38. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
[TBL] [Abstract][Full Text] [Related]
39. Risk of breast cancer among French-Canadian women, noncarriers of more frequent BRCA1/2 mutations and consumption of total energy, coffee, and alcohol.
Bissonauth V; Shatenstein B; Fafard E; Maugard C; Robidoux A; Narod S; Ghadirian P
Breast J; 2009; 15 Suppl 1():S63-71. PubMed ID: 19775332
[TBL] [Abstract][Full Text] [Related]
40. [Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers].
Hüttelová R; Kleibl Z; Rezátová J; Krutílková V; Foretová L; Novotný J; Kotlas J; Zikán M; Pohlreich P
Klin Onkol; 2009; 22 Suppl():S69-74. PubMed ID: 19764403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
